drugset

drugset / Trial / NCT01146938

A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

NCT01146938 ↗

Phase 1 Completed 18 enrolled Boryung Pharmaceutical Co., Ltd Kyungpook National University Hospital · collab Yonsei University · collab

Non-randomizedParallel-groupOpen-label

Summary

To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers

Timeline

Start: 2010-05
Primary completion: 2011-02
Completion: 2011-02

Publications

Kim CO, Lee HW, Oh ES, Seong SJ, Kim DY, Lee J, Ahn SH, Yoon YR, Cho CM, Park MS. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan. J Cardiovasc Pharmacol. 2013 Dec;62(6):524-9. doi: 10.1097/FJC.0000000000000010.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Fimasartan	Small molecule	120 mg	Oral

Indications